In Europe, Emerging Novel Factor Xa Inhibitors Are Set to Displace Use of Low-Molecular-Weight Heparins and Unfractionated

Surveyed Cardiologists Indicate They Would Be Willing to Replace Use of Low-Molecular-Weight Heparins and Unfractionated Heparins with Emerging Agents Such as Apixaban, Otamixaban and Adomiparin, According to New Report from Arlington Medical Resources

EXTON, Pa.--(BUSINESS WIRE)-- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that, in the five major European markets (France, Germany, Italy, Spain and the United Kingdom), most patients with acute coronary syndrome (ACS) who have an intensive care unit (ICU) stay are treated with either low-molecular-weight heparin or unfractionated heparin. However, promising emerging novel factor Xa inhibitors such as Pfizer/Bristol-Myers Squibb’s apixaban, Sanofi-Aventis’s otamixaban and Momenta Pharmaceuticals’ adomiparin have the potential to replace a large share of current prescribing of low-molecular-weight heparins and unfractionated heparins.

The new AMR report entitled Anticoagulants—Prevention of Ischemic Complications Associated with Acute Coronary Syndrome (Europe) finds that because of their lack of food-food or food-drug interactions, formal approval for use in ACS, and favorable safety profiles, low-molecular-weight heparins and unfractionated heparins command a high patient share in the ACS market and present stiff competition to the uptake current brands and emerging therapies. Indeed, the report findings reveal that GlaxoSmithKline’s currently marketed Arixtra (fondaparinux) is significantly limited in Europe as only about 12 percent of ACS patients who have an ICU stay are treated with this drug.

“Acute coronary syndrome has an expanding and aging patient population, which makes it one of the most important indications to monitor for hospital anticoagulant use in the major European markets,” said AMR Analyst James Andersen. “Medical treatment for prevention of ischemic complications associated with this indication currently accounts for nearly seven percent of overall anticoagulant course prescribing in Europe and we expect this number to grow as the European population ages.”

About the Report

AMR’s Anticoagulants—Prevention of Ischemic Complications Associated with Acute Coronary Syndrome (Europe) presents a detailed analysis of hospital patient-level data and provides insight on the patient population, prescribing physicians and product usage in France, Germany, Italy, Spain and the United Kingdom. Additional primary research with 100 European cardiologists provides insight into their treatment practices and their perceptions of current and emerging inpatient anticoagulant therapies used for prevention of ischemic complications associated with ACS. The report also provides reasons behind physicians’ product preferences, factors driving prescribing patterns and receptivity to emerging agents.

About AMR

AMR (www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.



CONTACT:

Decision Resources, Inc.
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  Europe  North America  Pennsylvania

INDUSTRY KEYWORDS:   Health  Biotechnology  Cardiology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.